我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
33
21 进行中
药物批准
4
批准总数
监管机构
1
监管机构数
成立时间
2003
进行中（未招募）
21
63.6%
已完成
12
36.4%
FDA
Food and Drug Administration
- Formation Bio appointed four senior executives including Louis Brenner, MD as Chief Medical Officer and Daniel Neil, PhD as Chief Technology Officer to strengthen its AI-native pharmaceutical model. - Former Pfizer CFO Frank D'Amelio and ex-Incyte CSO Dashyant Dhanak, PhD joined as Strategic Advisors to guide the company's drug licensing and acquisition decisions. - The leadership expansion supports Formation Bio's plan to grow its pipeline from current assets to 10-15 drug candidates over the next 3-5 years. - The company recently secured a €545M out-licensing deal and added a new autoimmune disease asset to its development portfolio.
